Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
Introduction The NOD SCID Il r NSG
2018-10-20
Introduction The NOD.SCID Il2rγ (NSG) mouse strain dramatically improved investigators’ ability to study human hematopoietic stem cell (HSC) engraftment (Rongvaux et al., 2013; Shultz et al., 2005). The NSG strain combines a series of mutations that inhibit the host’s immune system by different mec
-
Over the last few years gene editing by homologous
2018-10-20
Over the last few years, gene editing by homologous recombination (HR) has been widely used in human NSC59984 to avoid undesirable transgene insertion. HR efficacy is very limited in human cells, estimated at one HR event per 106 cells; however, the potential application of HR in human cells has be
-
Although the FDA considers analogous cell product data
2018-10-20
Although the FDA considers analogous cell product data an acceptable option for preclinical studies, it requires substantial similarity between analogous animal and human products (FDA, 2013). Due to the significant differences in the innate and adaptive immune system (Mestas and Hughes, 2004), hema
-
Hello world!
2018-07-29
15004 records 1001/1001 page Previous First page 上5页 1001